Search research articles
Contact Us
Filters
Showing results (61-70 of 205) with videos related to
Page
of 21
Sort By:
Cancer Genetics and Cytogenetics
|
February 14, 2009
Genomic translocation breakpoint sequences are conserved in BCR-ABL1 cell lines despite the presence of amplification
David M Ross, Lisa Schafranek, Timothy P Hughes, et al.
Plos One
|
February 1, 2018
ABCC6 plays a significant role in the transport of nilotinib and dasatinib, and contributes to TKI resistance in vitro, in both cell lines and primary patient mononuclear cells
Laura N Eadie, Phuong Dang, Jarrad M Goyne, et al.
Blood Neoplasia
|
December 22, 2025
Do all patients with chronic phase CML require a diagnostic bone marrow biopsy in the modern TKI era?
Noel F T Fong, David M Ross, David T Yeung, et al.
Blood
|
April 10, 2008
Dasatinib suppresses in vitro natural killer cell cytotoxicity
Stephen J Blake, A Bruce Lyons, Cara K Fraser, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 1, 2018
Management of Pregnancy in Women With Chronic Myeloid Leukemia
David M Ross, Kate L Burbury, Andrew P Grigg, et al.
Blood
|
July 17, 2010
The poor response to imatinib observed in CML patients with low OCT-1 activity is not attributable to lower uptake of imatinib into their CD34+ cells
Jane R Engler, Amity Frede, Verity Saunders, et al.
Blood
|
April 6, 2007
Imatinib increases the intracellular concentration of nilotinib, which may explain the observed synergy between these drugs
Deborah L White, Verity A Saunders, Steven R Quinn, et al.
The Journal of Clinical Endocrinology and Metabolism
|
May 15, 2010
Plasma adiponectin levels are markedly elevated in imatinib-treated chronic myeloid leukemia (CML) patients: a mechanism for improved insulin sensitivity in type 2 diabetic CML patients?
Stephen Fitter, Kate Vandyke, Christopher G Schultz, et al.
International Journal of Molecular Sciences
|
May 4, 2026
Allosteric and ATP-Pocket BCR::ABL1 Inhibition In Vitro, and Characterising Ex Vivo Thrombo-Inflammatory Biomarkers and Thrombin Generation in Asciminib-Treated CML Patients
Musab M A Omar, Majed A Alanazi, David T Yeung, et al.
Experimental Hematology
|
September 30, 2009
Dasatinib inhibits the secretion of TNF-alpha following TLR stimulation in vitro and in vivo
Cara K Fraser, Erin L Lousberg, Raman Kumar, et al.
Page
of 21
Search research articles
Search
Showing results (61-70 of 205) with videos related to
Sort By:
Page
of 21
Cancer Genetics and Cytogenetics
|
February 14, 2009
Genomic translocation breakpoint sequences are conserved in BCR-ABL1 cell lines despite the presence of amplification
David M Ross, Lisa Schafranek, Timothy P Hughes, et al.
Plos One
|
February 1, 2018
ABCC6 plays a significant role in the transport of nilotinib and dasatinib, and contributes to TKI resistance in vitro, in both cell lines and primary patient mononuclear cells
Laura N Eadie, Phuong Dang, Jarrad M Goyne, et al.
Blood Neoplasia
|
December 22, 2025
Do all patients with chronic phase CML require a diagnostic bone marrow biopsy in the modern TKI era?
Noel F T Fong, David M Ross, David T Yeung, et al.
Blood
|
April 10, 2008
Dasatinib suppresses in vitro natural killer cell cytotoxicity
Stephen J Blake, A Bruce Lyons, Cara K Fraser, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 1, 2018
Management of Pregnancy in Women With Chronic Myeloid Leukemia
David M Ross, Kate L Burbury, Andrew P Grigg, et al.
Blood
|
July 17, 2010
The poor response to imatinib observed in CML patients with low OCT-1 activity is not attributable to lower uptake of imatinib into their CD34+ cells
Jane R Engler, Amity Frede, Verity Saunders, et al.
Blood
|
April 6, 2007
Imatinib increases the intracellular concentration of nilotinib, which may explain the observed synergy between these drugs
Deborah L White, Verity A Saunders, Steven R Quinn, et al.
The Journal of Clinical Endocrinology and Metabolism
|
May 15, 2010
Plasma adiponectin levels are markedly elevated in imatinib-treated chronic myeloid leukemia (CML) patients: a mechanism for improved insulin sensitivity in type 2 diabetic CML patients?
Stephen Fitter, Kate Vandyke, Christopher G Schultz, et al.
International Journal of Molecular Sciences
|
May 4, 2026
Allosteric and ATP-Pocket BCR::ABL1 Inhibition In Vitro, and Characterising Ex Vivo Thrombo-Inflammatory Biomarkers and Thrombin Generation in Asciminib-Treated CML Patients
Musab M A Omar, Majed A Alanazi, David T Yeung, et al.
Experimental Hematology
|
September 30, 2009
Dasatinib inhibits the secretion of TNF-alpha following TLR stimulation in vitro and in vivo
Cara K Fraser, Erin L Lousberg, Raman Kumar, et al.
Page
of 21